Furthermore, they support the feasibility of targeting the AurkA/TPX2 complex and they pave the way for further research on the development of effective anticancer therapies specifically affecting oncogenic AurkA/TPX2 functions and thus mitigating mitotic defects, aneuploidy, and chromosomal instability in cancer cells. Here, TPX2 is linked to cancer.